Emile R. Mohler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emile R. Mohler has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Li
Department of Radiology, Department of Bioengineering, Laboratory for Structural NMRImaging (LSNI), Philadelphia, PA, USA
3 shared publications - Erin K. Englund
Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
3 shared publications - Felix. W. Wehrli
Laboratory for Structural, Physiologic and Functional Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
3 shared publications - Michael C. Langham
Laboratory for Structural, Physiologic and Functional Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, PA
3 shared publications - Thomas F. Floyd
From the Departments of Anesthesiology (A.S.K., M.C., T.F.F.), Surgery (T.V.B.), and Neurological Surgery (R.M.G.), Stony Brook University Medical Center, Stony Brook, New York; Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York (A.S.K., T.F.F.); Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania (R.C.M., S.S.S., A.G.Y.); and Institute of Physics, University of Campinas, Campinas, São Paulo, Brazil (R.C.M.).
3 shared publications - Zachary B Rodgers
Department of Radiology, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA, 19104, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 70
Combined measurement of perfusion, venous oxygen saturation, and skeletal muscle T2* during reactive hyperemia in the leg
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 70
Open AccessCombined measurement of perfusion, venous oxygen saturation, and skeletal muscle T2* during reactive hyperemia in the leg
- Open Access
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 17
Quantitative CMR markers of impaired vascular reactivity associated with age and peripheral artery disease
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 17
Open AccessQuantitative CMR markers of impaired vascular reactivity associated with age and peripheral artery disease
- Open Access
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 100
Vessel-wall imaging and quantification of flow-mediated dilation using water-selective 3D SSFP-echo
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 100
Open AccessVessel-wall imaging and quantification of flow-mediated dilation using water-selective 3D SSFP-echo
- Open Access
- 14 October 2011
- Published by SAGE Publications in Vascular Medicine
- Vol. 16 (5) , 346-353
Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication
Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia. This study evaluated multiple doses of TSC in patients with peripheral artery disease (PAD) and hypothesized that a preliminary dose–response relationship could be identified on peak walking time (PWT). Forty-eight patients with symptomatic PAD and an ankle–brachial index < 0.90 were included, while critical limb ischemia, recent revascularization, and exercise limited by symptoms other than claudication were exclusionary. Patients were randomized to placebo or eight dosing levels of TSC ranging from 0.25 mg/kg to 2.0 mg/kg given intravenously once daily for 5 days. Subjects were tested on a graded treadmill protocol to claudication-limited PWT with the change to Day 5 as primary. A cubic regression was fit to detect a pre-specified inverted U-shaped dose–response relationship (65% power). Patient-reported walking distance from the Walking Impairment Questionnaire was a secondary endpoint. Adverse events were not predominant on any drug dose relative to placebo. Changes in PWT demonstrated a cubic trend for dose ( p = 0.07, r = 0.39, r2 = 0.15) with morphologic signals of benefit at doses above 1.00 mg/kg after both the first and fifth dosing days. Similar improvements occurred with the walking distance score at doses above 1.00 mg/kg. In conclusion, TSC was safe and well tolerated at all doses. Notable signals of benefit were observed at higher doses for both PWT and patient-perceived walking distance. These results support a phase II study to define the optimal dose for longer-term therapy with TSC. Clinical Trial Registration – URL: http://www.clinicaltrials.gov . Unique identifier: NCT00725881
- 14 October 2011
- Published by SAGE Publications in Vascular Medicine
- Vol. 16 (5) , 346-353
Open AccessEvaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication
Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia. This study evaluated multiple doses of TSC in patients with peripheral artery disease (PAD) and hypothesized that a preliminary dose–response relationship could be identified on peak walking time (PWT). Forty-eight patients with symptomatic PAD and an ankle–brachial index < 0.90 were included, while critical limb ischemia, recent revascularization, and exercise limited by symptoms other than claudication were exclusionary. Patients were randomized to placebo or eight dosing levels of TSC ranging from 0.25 mg/kg to 2.0 mg/kg given intravenously once daily for 5 days. Subjects were tested on a graded treadmill protocol to claudication-limited PWT with the change to Day 5 as primary. A cubic regression was fit to detect a pre-specified inverted U-shaped dose–response relationship (65% power). Patient-reported walking distance from the Walking Impairment Questionnaire was a secondary endpoint. Adverse events were not predominant on any drug dose relative to placebo. Changes in PWT demonstrated a cubic trend for dose ( p = 0.07, r = 0.39, r2 = 0.15) with morphologic signals of benefit at doses above 1.00 mg/kg after both the first and fifth dosing days. Similar improvements occurred with the walking distance score at doses above 1.00 mg/kg. In conclusion, TSC was safe and well tolerated at all doses. Notable signals of benefit were observed at higher doses for both PWT and patient-perceived walking distance. These results support a phase II study to define the optimal dose for longer-term therapy with TSC. Clinical Trial Registration – URL: http://www.clinicaltrials.gov . Unique identifier: NCT00725881
- 1 March 2007
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 4 (3) , 151-162
Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines
Approximately one-third of patients with diabetes have peripheral arterial disease (PAD) and concomitant diabetes amplifies the already high risk of atherothrombotic events present in those with PAD. Here, Emile R Mohler III discusses atherothrombosis and PAD in patients with diabetes in the context of the 2006 American College of Cardiology/American Heart Association guidelines for PAD management. The increased risk of atherothrombotic events present in all patients with peripheral arterial disease (PAD) is amplified with concomitant diabetes. Moreover, diabetes is associated with increased PAD severity. This Review summarizes atherothrombosis and PAD in patients with diabetes, and American College of Cardiology and American Heart Association guidelines for management of patients with PAD. Patients with PAD and diabetes require optimal limb care and aggressive cardiovascular risk reduction. An LDL cholesterol level of less than 1.8 mmol/l (<70 mg/dl) is the therapeutic goal in these patients, and this target should be pursued using an aggressive statin regimen. Fibrate therapy can also be indicated. β-blockers and angiotensin-converting-enzyme inhibitors reduce cardiovascular events in high-risk patient populations, and these agents are recommended for use in patients with both diabetes and PAD. Blood pressure of less than 130/80 mmHg should be achieved, and glycated hemoglobin should be reduced to below 7%. Patients should also receive indefinite antiplatelet therapy with aspirin or clopidogrel. For patients with claudication, a supervised exercise program and cilostazol therapy to improve PAD symptoms and walking distance form the main noninvasive components of therapy. Revascularization can also be indicated in carefully selected patients with claudication. For patients with critical limb ischemia, diagnostic testing by a vascular specialist will determine whether revascularization or amputation is feasible.
- 1 March 2007
- Published by Springer Nature in Nature Clinical Practice Cardiovascular Medicine
- Vol. 4 (3) , 151-162
Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines
Approximately one-third of patients with diabetes have peripheral arterial disease (PAD) and concomitant diabetes amplifies the already high risk of atherothrombotic events present in those with PAD. Here, Emile R Mohler III discusses atherothrombosis and PAD in patients with diabetes in the context of the 2006 American College of Cardiology/American Heart Association guidelines for PAD management. The increased risk of atherothrombotic events present in all patients with peripheral arterial disease (PAD) is amplified with concomitant diabetes. Moreover, diabetes is associated with increased PAD severity. This Review summarizes atherothrombosis and PAD in patients with diabetes, and American College of Cardiology and American Heart Association guidelines for management of patients with PAD. Patients with PAD and diabetes require optimal limb care and aggressive cardiovascular risk reduction. An LDL cholesterol level of less than 1.8 mmol/l (<70 mg/dl) is the therapeutic goal in these patients, and this target should be pursued using an aggressive statin regimen. Fibrate therapy can also be indicated. β-blockers and angiotensin-converting-enzyme inhibitors reduce cardiovascular events in high-risk patient populations, and these agents are recommended for use in patients with both diabetes and PAD. Blood pressure of less than 130/80 mmHg should be achieved, and glycated hemoglobin should be reduced to below 7%. Patients should also receive indefinite antiplatelet therapy with aspirin or clopidogrel. For patients with claudication, a supervised exercise program and cilostazol therapy to improve PAD symptoms and walking distance form the main noninvasive components of therapy. Revascularization can also be indicated in carefully selected patients with claudication. For patients with critical limb ischemia, diagnostic testing by a vascular specialist will determine whether revascularization or amputation is feasible.